ClinicalTrials.gg
Not yet recruitingNCT07948174Updated Nov 19, 2026

Agreement Between Pleth Variability Index and Arterial Pulse Pressure Variation During Gynecological Laparoscopic Surgery

An observational study in Pleth Variability Index and Pulse Pressure Variation, sponsored by Istinye University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Istinye University · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This prospective observational study aims to evaluate the agreement between the non-invasive Pleth Variability Index (PVi) and manually calculated invasive Pulse Pressure Variation (PPV) during gynecological laparoscopic surgery. Measurements will be obtained at five predefined intraoperative time points corresponding to baseline supine positioning, pneumoperitoneum, 15-degree Trendelenburg positioning, 30-degree Trendelenburg positioning, and return to the supine position after desufflation. The study will assess changes in the relationship and agreement between these two hemodynamic parameters under different surgical conditions.

02

Conditions studied

  • Pleth Variability Index
  • Pulse Pressure Variation
03

In context

Lead sponsor

Istinye University is the lead sponsor of 224 studies on the registry; 96 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of 45 female patients aged 18-65 years with ASA physical status I-III who are scheduled to undergo elective gynecological laparoscopic surgery, including hysterectomy, myomectomy, and gynecological oncological procedures. All participants will have clinically indicated invasive arterial monitoring, sinus rhythm, and mechanical ventilation with a fixed tidal volume of 8 mL/kg of ideal body weight. Patients meeting the predefined inclusion and exclusion criteria will be enrolled in this prospective observational study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18-65 years.
  • (ASA) physical status I-III.
  • Scheduled for elective gynecological laparoscopic surgery, including hysterectomy, myomectomy, or gynecological oncological surgery.
  • Clinically indicated invasive arterial monitoring during surgery.
  • Sinus rhythm without arrhythmias.
  • Mechanical ventilation with a fixed tidal volume of 8 mL/kg of ideal body weight.

Exclusion criteria

Exclusion Criteria:

  • Atrial fibrillation or frequent supraventricular or ventricular premature contractions.
  • Severe peripheral arterial disease or Raynaud phenomenon.
  • History of open-heart surgery or severe valvular heart disease, particularly aortic regurgitation.
  • Increased intracranial pressure syndrome.
  • Pulmonary pathology requiring a tidal volume below 8 mL/kg.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Agreement Between Pleth Variability Index (PVi) and Manually Calculated Invasive Pulse Pressure Variation (PPV)

    Correlation coefficients and Bland-Altman bias and 95% limits of agreement between PVi and manually calculated invasive PPV will be evaluated at four intraoperative conditions: baseline supine position (T1), pneumoperitoneum in supine position (T2), pneumoperitoneum with 15-degree Trendelenburg positioning (T3), and pneumoperitoneum with 30-degree Trendelenburg positioning (T4).

    Time frame: Intraoperatively, 5 minutes after establishment of each predefined condition at T1, T2, T3, and T4.

07

Study locations

1 site
08

References and documents

Publications

  • Park JC, Yun SH. Analysis of Patterns of Pulse Oximeter Perfusion Index According to Postural Change During Gynecological Surgery. J Cell Mol Anesth. 2025;10(4):e162363. doi:10.5812/jcma- 162363.
  • Oh C, Noh C, Baek S, Lee SY, Hong B. Comparison between conventional pleth variability index (PVI) and Rainbow PVI (RPVI) in non-cardiothoracic surgery: a retrospective study. Korean J Anesthesiol. 2025 Jul 29. doi: 10.4097/kja.25307. Online ahead of print. PubMed 40726344 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Nov 21, 2026
Primary completionEst.
Feb 21, 2027
CompletionEst.
Mar 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948174
Lead sponsor
Istinye University
Responsible party
İlke Dolgun (Assoc. prof, Istinye University) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 21, 2026 (estimated)
Primary completion
Feb 21, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

ilke dolğun
Contact
ilkeser2004@gmail.com
+905555485632

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion